<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721756</url>
  </required_header>
  <id_info>
    <org_study_id>18F-LY3546117-01</org_study_id>
    <nct_id>NCT04721756</nct_id>
  </id_info>
  <brief_title>Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging</brief_title>
  <official_title>A Phase I Study Evaluating the Safety and Imaging Characteristics of 18F-LY3546117 Injection in Subjects Who Are Undergoing Treatment With Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immuno-Oncology (IO) therapies have revolutionized cancer therapy and are becoming the&#xD;
      standard of care for many cancers. Monitoring how well IO therapies work against cancer is&#xD;
      difficult due to the complexity of the immune system and the fact that an immune response may&#xD;
      initially increase, rather than decrease, the size of a tumor. An early response marker would&#xD;
      be beneficial to determine which patients should remain on a given treatment or combination&#xD;
      of treatments, and which patients should seek other treatment options. 18F-LY3546117 is a&#xD;
      radiolabeled tracer that binds to a specific protein (Granzyme B) that is found in the human&#xD;
      immune system and is thought to trigger programmed cell death. It is thought that imaging&#xD;
      Granzyme B activity in tumors and elsewhere in the body using a Positron Emission Tomography&#xD;
      (PET) scan will allow doctors to monitor the progress of IO therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Uptake of 18F-LY3546117 in tumor foci and other organs of the body</measure>
    <time_frame>Day 14 up to Day 42 of immune checkpoint inhibitor therapy</time_frame>
    <description>Visual uptake in the tumor as assessed by sponsor expert reader (Yes/No)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2: Uptake of 18F-LY3546117 in tumor foci and other organs of the body</measure>
    <time_frame>At immune checkpoint inhibitor treatment response (Day 42 up to 6 months post-treatment)</time_frame>
    <description>Visual uptake in the tumor as assessed by sponsor expert reader (Yes/No)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neoplasms</condition>
  <condition>Neoplasms Malignant</condition>
  <arm_group>
    <arm_group_label>18F-LY3546117 Scan Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-LY3546117 PET scan at baseline and between 14-42 days after initiation of immune checkpoint therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-LY3546117 Scan Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-LY3546117 PET scan at time of immune checkpoint therapy response</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-LY3546117 Injection</intervention_name>
    <description>370 megabecquerel (MBq) intravenous injection</description>
    <arm_group_label>18F-LY3546117 Scan Cohort 1</arm_group_label>
    <arm_group_label>18F-LY3546117 Scan Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET Scan</intervention_name>
    <description>positron emission tomography (PET) scan</description>
    <arm_group_label>18F-LY3546117 Scan Cohort 1</arm_group_label>
    <arm_group_label>18F-LY3546117 Scan Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Cohort 1):&#xD;
&#xD;
          -  At least one imageable tumor greater than or equal to 15 mm in the longest diameter&#xD;
&#xD;
          -  Confirmed diagnosis of cancer with a high likelihood of response to immuno-oncology&#xD;
             therapy (melanoma or non-small cell lung cancer, or other malignancies with sponsor&#xD;
             approval) and planned mono- or combination therapy with immuno-oncology therapy&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
        Inclusion Criteria (Cohort 2):&#xD;
&#xD;
          -  At least one imageable tumor greater than or equal to 15 mm in the longest diameter or&#xD;
             a tumor assessable by PET in the opinion of the radiologist&#xD;
&#xD;
          -  Received treatment with an immune checkpoint inhibitor with evidence of response&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who plan to receive chemotherapy or radiation therapy during study&#xD;
             participation&#xD;
&#xD;
          -  Prior history of failed immune checkpoint inhibitor therapy&#xD;
&#xD;
          -  Subjects who require steroid or other immunosuppressive medications within 2 weeks of&#xD;
             the PET scan.&#xD;
&#xD;
          -  Females of childbearing potential who are not surgically sterile, not refraining from&#xD;
             sexual activity, or not using effective methods of contraception. Females of&#xD;
             childbearing potential must not be pregnant or breastfeeding at screening and agree to&#xD;
             avoid becoming pregnant for 24 hours following study drug administration.&#xD;
&#xD;
          -  Females and males must agree to refrain from sexual activity or to use effective&#xD;
             contraceptive methods for 24 hours following study drug administration and during&#xD;
             study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avid Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avid Clinical Operations</last_name>
    <phone>215-298-0700</phone>
    <email>clinicaloperations@avidrp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Olivia Newton-John Cancer Institute and Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Tina Chen</last_name>
      <phone>+613 94965748</phone>
      <email>Tina.CHEN@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Prof. Andrew Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

